Workspaces
Log in Sign up
← Atlas Theme · spans 1 topics

Evidence standards now loosen for favored therapies and tighten for disfavored ones.

The same FDA is opening novel endpoints and frameworks for Alzheimer's prevention and rare diseases while mounting a fresh statistical hunt for 'safety risks that have not yet been identified' in a 25-year-old abortion pill.

1
Topics it spans
3
Findings citing it
—
Evidence window
The convergence

The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:

Science & Health
FDA Launches NAIN and the Alzheimer's Prevention Accelerator as HHS Updates the National Alzheimer's Plan — Prevention, Not Just Treatment, Becomes the Regulatory Project

The agency is signaling openness to novel, more achievable evidentiary approaches for a politically championed prevention frontier.

Science & Health
FDA Launches the Rare Disease Framework Initiative — White Paper and Oct 28 Public Meeting to Rethink Evidence Standards for Small Populations

The initiative pledges to remove barriers and customize evidence requirements for a field the administration has publicly embraced.

Science & Health
FDA Tells a Federal Court Its Mifepristone Safety Review Will Be Complete by March 2027 — Teed Up for Possible Rollback of Mail-Order Abortion Pills

For a two-decade-old drug whose access the administration aims to restrict, the agency is manufacturing new evidentiary doubt — the same dial turned the other direction.